RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2021)
RedHill Biopharma (RDHL) reported Non-Current Debt of $83.6 million for Q4 2021, up 2.74% year-over-year from $81.4 million in Q4 2020, and up 2.74% quarter-over-quarter from $81.4 million in Q4 2020.
RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2021) Analysis & Trends
RedHill Biopharma (RDHL) has 2 years of Non-Current Debt data on file, last reported at $83.6 million in Q4 2021.
- Non-Current Debt for Q4 2021 came in at $83.6 million, up 2.74% year-over-year; the trailing twelve-month figure through Dec 2021 was $83.6 million (up 2.74% YoY), and the FY2021 annual result was $83.6 million, up 2.74% from the prior year.
- Non-Current Debt advanced to $83.6 million in Q4 2021 per RDHL's latest filing, from $81.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $83.6 million in Q4 2021 and troughed at $81.4 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 569.60 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | RedHill Biopharma | 142.34 Mn | 142.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 83.62 Mn |
| Dec 31, 2021 | 83.62 Mn |
| Dec 31, 2020 | 81.39 Mn |
| Dec 31, 2020 | 81.39 Mn |